Table 4. Association of Lp-PLA2 with total CVD among subgroups.
VariablesHR (95% CI) by quartile of Lp-PLA2aP for trend
Q1Q2Q3Q4
Individuals not on hormone therapy (1098 cases/1162 subcohort)
    Lp-PLA2 activity
        Adjusted for age and race/ethnicity1.001.07 (0.80–1.44)1.35 (1.01–1.81)1.70 (1.26–2.28)0.0001
        Fully adjustedb1.000.98 (0.70–1.37)1.06 (0.74–1.51)1.17 (0.97–1.72)0.37
    Lp-PLA2 mass
        Adjusted for age and race/ethnicity1.001.12 (0.84–1.52)1.28 (0.95–1.73)1.65 (1.23–2.20)0.0004
        Fully adjusted1.001.28 (0.90–1.81)1.24 (0.86–1.80)1.75 (1.20–2.54)0.005
Individuals on hormone therapy (719 cases/830 subcohort)
    Lp-PLA2 Activity
        Adjusted for age and race/ethnicity1.000.99 (0.67–1.47)1.12 (0.77–1.64)1.24 (0.84–1.83)0.22
        Fully adjusteda1.001.03 (0.66–1.63)0.99 (0.63–1.55)0.90 (0.53–1.52)0.66
    Lp-PLA2 mass
        Adjusted for age and race/ethnicity1.000.98 (0.65–1.48)1.38 (0.92–2.07)1.57 (1.06–2.33)0.007
        Fully adjusteda1.001.12 (0.71–1.76)1.43 (0.90–2.26)1.66 (1.03–2.69)0.022
Nondiabetic individuals (1632 cases/ 1899 subcohort)
    Lp-PLA2 activity
        Adjusted for age and race/ethnicity1.001.21 (0.98–1.50)1.16 (0.94–1.43)1.49 (1.21–1.82)0.0004
        Fully adjustedb1.001.15 (0.92–1.45)0.97 (0.76–1.24)0.99 (0.76–1.31)0.57
    Lp-PLA2 mass
        Adjusted for age and race/ethnicity1.001.13 (0.91–1.40)1.42 (1.15–1.76)1.78 (1.45–2.18)<0.0001
        Fully adjusted1.001.22 (0.97–1.54)1.35 (1.06–1.71)1.75 (1.37–2.24)<0.0001
Individuals not on statins (1687 cases/1831 subcohort)
    Lp-PLA2 activity
        Adjusted for age and race/ethnicity1.001.30 (1.05–1.60)1.25 (1.02–1.55)1.54 (1.25–1.90)0.0002
        Fully adjusted1.001.26 (0.99–1.59)1.00 (0.78–1.28)1.02 (0.77–1.36)0.58
    Lp-PLA2 mass
        Adjusted for age and race/ethnicity1.001.10 (0.88–1.37)1.44 (1.16–1.78)1.71 (1.39–2.10)<0.0001
        Fully adjusted1.001.23 (0.96–1.57)1.47 (1.15–1.88)1.74 (1.35–2.25)<0.0001
Nonusers of hormone therapy and statins, without prior diabetes or angina (876 cases/978 subcohort)
    Lp-PLA2 activity
        Adjusted for age and race/ethnicity1.001.12 (0.80–1.57)1.38 (0.99–1.94)1.60 (1.13–2.26)0.003
        Fully adjusted1.001.01 (0.68–1.48)1.05 (0.70–1.58)0.98 (0.62–1.56)0.98
    Lp-PLA2 mass
        Adjusted for age and race/ethnicity1.001.06 (0.74–1.50)1.34 (0.95–1.89)1.72 (1.23–2.40)0.0004
        Fully adjusted1.001.07 (0.72–1.59)1.21 (0.81–1.80)1.65 (1.09–2.50)0.013
  • a Cutpoints per subgroup-specific quartile are 166.5, 194.3, 227.4 mmol/min/mL for activity and 417.2, 506.5, 615.4 ng/mL for mass among those not on hormone therapy; 133.6, 158.6, 193.8 mmol/min/mL for activity and 363.1, 436.6, 528.7 ng/mL for mass among those on hormone therapy; 146.6, 179.0, 211.9 mmol/min/mL for activity and 388.2, 476.6, 572.4 ng/mL for mass among nondiabetics; 145.3, 179.1, 212.5 mmol/min/mL for activity and 388.1, 477.7, 576.4 ng/mL for mass among those not on statins; and 166.8, 195.1, 228.0 mmol/min/mL for activity and 429.9, 511.9, 620.1 ng/mL for mass among the healthy nonusers of hormone therapy.

  • b Fully adjusted, adjusted for age, race/ethnicity, prior diabetes, angina, statin use, current smoking, the natural logs of SBP, total and HDL cholesterol and CRP, family history of premature MI, and Hb A1c among diabetic patients. Models are additionally adjusted for current and past use of hormone therapy as appropriate.